Genetically Modified Caco-2 Cells With Improved Cytochrome P450 Metabolic Capacity

Area of Science:

• Pharmacology
• Cell Biology
• Drug Metabolism

Background:

• Caco-2 cells are a standard model for intestinal absorption.
• However, they lack key drug-metabolizing enzymes like cytochrome P450 (CYP) 3A4 and CYP2C9.
• This limits their utility in studying intestinal drug metabolism.

Purpose of the Study:

• To develop novel Caco-2 cell sublines with enhanced CYP expression and activity.
• To improve the in vitro model for intestinal drug metabolism studies.

Main Methods:

• Created two Caco-2 sublines expressing chimeric constitutive androstane (mCAR) or pregnane X receptors (PXR).
• Characterized the metabolic and absorption properties of these modified cells.
• Assessed mRNA expression of transporters and differentiation markers.

Main Results:

• Modified Caco-2 sublines showed elevated mRNA expression of transporters and differentiation markers.
• Permeation properties did not significantly differ from wild-type Caco-2 cells.
• Metabolic activity was substantially increased, with CYP3A4 activity up to 20-fold higher than in vitamin D-treated wild-type cells.

Conclusions:

• Novel Caco-2 sublines expressing chimeric mCAR/PXR receptors exhibit significantly enhanced CYP metabolic activity.
• These cells provide an improved in vitro model for studying intestinal drug metabolism and drug-drug interactions.
• The enhanced metabolic capacity surpasses currently available models.